ReviewFrontiers in oncology2026

Therapeutic advances in HR+/HER2- advanced breast cancer after failure of CDK4/6 inhibitor therapy.

Mengqi Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.